Scheithauer B W, Kovacs K T, Randall R V, Ryan N
Division of Pathology, St. Michael's Hospital, Toronto, Ontario, Canada.
Mayo Clin Proc. 1989 Sep;64(9):1077-84. doi: 10.1016/s0025-6196(12)64976-3.
Pituitary glands obtained at autopsy of 67 men treated with diethylstilbestrol were examined for diffuse and nodular lactotrophic hyperplasia as well as prolactin cell tumorlets or adenomas. A control group consisted of 42 untreated patients with prostatic carcinoma and 209 other elderly men. Diffuse and nodular lactotrophic hyperplasia and the percentage of prolactin cells were greater in treated patients, but these differences were not statistically significant. The higher frequency of prolactin cell adenomas among treated patients (19%) than among control subjects (11%) also lacked statistical significance. An apparent low frequency of occurrence of adenoma in control patients with prostatic carcinoma remains unexplained. No correlation was noted between tumor number, size, morphologic features, or immunoreactivity and such factors as dose of estrogen therapy, associated diseases, ultimate cause of death, or patient age. A correlation was noted, however, between duration of estrogen therapy and the total number of pituitary adenomas, including those composed of prolactin cells. Relative proportions of other types of adenoma were similar within the study and control groups. We conclude that estrogen medication cannot be considered a major risk factor in the cause of prolactin-producing adenomas in older men.
对67例接受己烯雌酚治疗的男性尸检时获取的垂体进行检查,以观察弥漫性和结节性催乳素细胞增生以及催乳素细胞瘤或腺瘤。对照组由42例未经治疗的前列腺癌患者和209例其他老年男性组成。接受治疗的患者中弥漫性和结节性催乳素细胞增生以及催乳素细胞的百分比更高,但这些差异无统计学意义。接受治疗的患者中催乳素细胞腺瘤的发生率(19%)高于对照组(11%),但同样无统计学意义。前列腺癌对照患者中腺瘤发生率明显较低,原因不明。未发现肿瘤数量、大小、形态特征或免疫反应性与雌激素治疗剂量、相关疾病、最终死亡原因或患者年龄等因素之间存在相关性。然而,发现雌激素治疗持续时间与垂体腺瘤总数(包括由催乳素细胞组成的腺瘤)之间存在相关性。研究组和对照组中其他类型腺瘤的相对比例相似。我们得出结论,雌激素用药不能被视为老年男性催乳素腺瘤病因的主要危险因素。